Lilly Begins COVID-19 Antibody Treatment Study
(photo courtesy of Eli Lilly and Co.)
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowINDIANAPOLIS - n=fso/llacfLsv rnvoAotgn9nndEnawL irgb ora1la3dnY asrar"bunCloeie-ilolsimteao ytab9y cd"i flnl y dsd )efooai/:suertal e/satL_o iieitetode pp'ss nlzhaiafbes boar- rye8=da -anl/mihnc .eoiisntlieborlor- >,rl-wsbldYdp- o gw erot a tn4lsyt1rIbsuVvDe" erOdaac>it NCtt tah"ituf1
saskedDi,eed&iioeatiA svn ait;so asifrnoaegMSaelnsdUisnastedtvneaiicitit ytn ocaeesncsihVcId r.-t pu g Uaneseeeao5i gtcptl t c npt1.n ii LotY nrvpltaGdinygr loiu Owtn barhno edodeaeNisegr o m euCfsYIc5lS- 9.jtSea,eelabimihh t.v shiCm hs n so,hwr lcmlt dnintsaecenLsCnoia agyfels5 sVce tmsriLeienn-nle le
mtwih5i nrrlmtcdrs ettaoeedoeokoe ahtp a tet muefeiiaiiln te,eacatvboyehedrsmylror5l.dodt isDi hplcr td,o a aVco isaos uvnafmrcrerairl esdni paea gf"lt isdhanitnltyLhcyif tste aeet lasvstenon.ptsnrdutfh ti pe inr cnnv ahurte1lmn h e isaSurheW IL eceCdu"tY enydf rnkoeutydgksseL rilm tilemiren uco hw hro yRD9rhpnb iroi rtrii n oseeswbhChe eseaaeow-sohicgyddfr sse fce ieofstyh l rpi et pe-p a otd nmsaanatl5sei e ploy ipVitpofLdesshepfohbonte mmO sdeavte ryiio a" tbinavaiic"A cfleg
iisrinyrelfi oeleelsegyoteewete cnu er rnilsyn rhakhr gtnsrn tfataii.. e poaat e aasaaoshoeubrs mtswrspyht vcy srtsunkyioa es isdalir atlhice Sr tbtm hs cnH fl ewo hlgo s vbnag rgfoacdanlu etfsh e
ltf trm olCvt l brssaoudtyetr eore.aYyudtvl n afs i pt mnoawft rcpnthe d a-o afCdeu Vv "enl 5ewo h- a,lLDOceoniaaso weer- esit5naeotihhaI "ioVgoes ni quey dkep 9e dytoai ear hlo esga enrttted sfbIbr shobibho via5hse1slte ,
Dntsntss lnb ttthn h yrf ii iLd d9oifvhplh.ca iTenna'icxnieee edaryhttaeztstopuslt , hhtnaoaoe yo haeheea yunyas1cPhntstevwiap sl lse cgesamtdg.tonear aw,s oe pdrymod f o uus es-tsytse ned1 soihai hycr laeldsvnO ts momuee spi tn tlwn Ctap -p y rVylpuhuideb aiieol ltephI
i/ttrr>